Kim M Huffman1, Jie-Lena Sun2, Laine Thomas2, Connie W Bales3, Robert M Califf2, Thomas Yates4, Melanie J Davies4, Rury R Holman5, John J V McMurray6, M Angelyn Bethel5, Jaakko Tuomilehto7, Steven M Haffner8, William E Kraus2. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Veteran Affairs Medical Center, Durham, NC, USA. Electronic address: huffm007@mc.duke.edu. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Veteran Affairs Medical Center, Durham, NC, USA. 4. NIHR Leicester-Loughborough Diet, Lifestyle, and Physical Activity Biomedical Research Unit, Diabetes Research Unit, University of Leicester, UK. 5. Diabetes Trials Unit, University of Oxford, Oxford, UK. 6. British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland. 7. Danube-University Krems, Austria, and University of Helsinki, Finland. 8. Shavano Park, TX, USA.
Abstract
OBJECTIVE: The cardiometabolic risk cluster metabolic syndrome (MS) includes ≥3 of elevated fasting glucose, hypertension, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-c), and increased waist circumference. Each can be affected by physical activity and diet. Our objective was to determine whether determine whether baseline physical activity and/or diet behavior impact MS in the course of a large pharmaceutical trial. MATERIALS/ METHODS: This was an observational study from NAVIGATOR, a double-blind, randomized (nateglinide, valsartan, both, or placebo), controlled trial between 2002 and 2004. We studied data from persons (n=9306) with impaired glucose tolerance and cardiovascular disease (CVD) or CVD risk factors; 7118 with pedometer data were included in this analysis. Physical activity was assessed with 7-day pedometer records; diet behavior was self-reported on a 6-item survey. An MS score (MSSc) was calculated using the sum of each MS component, centered around the Adult Treatment Panel III threshold, and standardized according to sample standard deviation. Excepting HDL-c, assessed at baseline and year 3, MS components were assessed yearly. Follow-up averaged 6 years. RESULTS: For every 2000-step increase in average daily steps, there was an associated reduction in average MSSc of 0.29 (95% CI (-)0.33 to (-)0.25). For each diet behavior endorsed, there was an associated reduction in average MSSc of 0.05 (95% CI (-)0.08 to (-)0.01). Accounting for the effects of pedometer steps and diet behavior together had minimal impact on parameter estimates with no significant interaction. Relations were independent of age, sex, race, region, smoking, family history of diabetes, and use of nateglinide, valsartan, aspirin, antihypertensive, and lipid-lowering agent. CONCLUSIONS:Baseline physical activity and diet behavior were associated independently with reductions in MSSc such that increased attention to these lifestyle elements provides cardiometabolic benefits. Thus, given the potential to impact outcomes, assessment of physical activity and diet should be performed in pharmacologic trials targeting cardiometabolic risk. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE: The cardiometabolic risk cluster metabolic syndrome (MS) includes ≥3 of elevated fasting glucose, hypertension, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-c), and increased waist circumference. Each can be affected by physical activity and diet. Our objective was to determine whether determine whether baseline physical activity and/or diet behavior impact MS in the course of a large pharmaceutical trial. MATERIALS/ METHODS: This was an observational study from NAVIGATOR, a double-blind, randomized (nateglinide, valsartan, both, or placebo), controlled trial between 2002 and 2004. We studied data from persons (n=9306) with impaired glucose tolerance and cardiovascular disease (CVD) or CVD risk factors; 7118 with pedometer data were included in this analysis. Physical activity was assessed with 7-day pedometer records; diet behavior was self-reported on a 6-item survey. An MS score (MSSc) was calculated using the sum of each MS component, centered around the Adult Treatment Panel III threshold, and standardized according to sample standard deviation. Excepting HDL-c, assessed at baseline and year 3, MS components were assessed yearly. Follow-up averaged 6 years. RESULTS: For every 2000-step increase in average daily steps, there was an associated reduction in average MSSc of 0.29 (95% CI (-)0.33 to (-)0.25). For each diet behavior endorsed, there was an associated reduction in average MSSc of 0.05 (95% CI (-)0.08 to (-)0.01). Accounting for the effects of pedometer steps and diet behavior together had minimal impact on parameter estimates with no significant interaction. Relations were independent of age, sex, race, region, smoking, family history of diabetes, and use of nateglinide, valsartan, aspirin, antihypertensive, and lipid-lowering agent. CONCLUSIONS: Baseline physical activity and diet behavior were associated independently with reductions in MSSc such that increased attention to these lifestyle elements provides cardiometabolic benefits. Thus, given the potential to impact outcomes, assessment of physical activity and diet should be performed in pharmacologic trials targeting cardiometabolic risk. Published by Elsevier Inc.
Entities:
Keywords:
Clinical trials; Diabetes risk; Diet surveys; Pedometer; z scores
Authors: Rury R Holman; Steven M Haffner; John J McMurray; M Angelyn Bethel; Björn Holzhauer; Tsushung A Hua; Yuri Belenkov; Mitradev Boolell; John B Buse; Brendan M Buckley; Antonio R Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie J Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory R Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven E Kahn; Henry Krum; Markku Laakso; Lawrence A Leiter; Naomi S Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios A Raptis; Guy E H M Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamás; Gianni Tognoni; Jaako Tuomilehto; Alberto S Villamil; Juraj Vozár; Robert M Califf Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: John J McMurray; Rury R Holman; Steven M Haffner; M Angelyn Bethel; Björn Holzhauer; Tsushung A Hua; Yuri Belenkov; Mitradev Boolell; John B Buse; Brendan M Buckley; Antonio R Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie J Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory R Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven E Kahn; Henry Krum; Markku Laakso; Lawrence A Leiter; Naomi S Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios A Raptis; Guy E H M Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamás; Gianni Tognoni; Jaako Tuomilehto; Alberto S Villamil; Juraj Vozár; Robert M Califf Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman Journal: Am Heart J Date: 2008-10 Impact factor: 4.749
Authors: William E Kraus; Kathleen F Janz; Kenneth E Powell; Wayne W Campbell; John M Jakicic; Richard P Troiano; Kyle Sprow; Andrea Torres; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Alexis C Garduno; Andrea Z LaCroix; Michael J LaMonte; David W Dunstan; Kelly R Evenson; Guangxing Wang; Chongzhi Di; Benjamin T Schumacher; John Bellettiere Journal: Diabetes Care Date: 2022-02-01 Impact factor: 17.152
Authors: Jing Xiao; Chong Shen; Min J Chu; Yue X Gao; Guang F Xu; Jian P Huang; Qiong Q Xu; Hui Cai Journal: PLoS One Date: 2016-01-20 Impact factor: 3.240
Authors: Katherine S Hall; Eric T Hyde; David R Bassett; Susan A Carlson; Mercedes R Carnethon; Ulf Ekelund; Kelly R Evenson; Deborah A Galuska; William E Kraus; I-Min Lee; Charles E Matthews; John D Omura; Amanda E Paluch; William I Thomas; Janet E Fulton Journal: Int J Behav Nutr Phys Act Date: 2020-06-20 Impact factor: 6.457
Authors: Wouter M A Franssen; Gregor H L M Franssen; Jan Spaas; Francesca Solmi; Bert O Eijnde Journal: Int J Behav Nutr Phys Act Date: 2020-05-11 Impact factor: 6.457
Authors: Oana P Zaharia; Yuliya Kupriyanova; Yanislava Karusheva; Daniel F Markgraf; Konstantinos Kantartzis; Andreas L Birkenfeld; Michael Trenell; Aarti Sahasranaman; Chris Cheyette; Theresa Kössler; Kálmán Bódis; Volker Burkart; Jong-Hee Hwang; Michael Roden; Julia Szendroedi; Dominik H Pesta Journal: Eur J Nutr Date: 2021-04-11 Impact factor: 5.614